Fidelis Capital Partners LLC Has $5.90 Million Stock Holdings in Eli Lilly and Company $LLY

Fidelis Capital Partners LLC reduced its stake in Eli Lilly and Company (NYSE:LLY) by 0.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,900 shares of the company’s stock after selling 55 shares during the period. Fidelis Capital Partners LLC’s holdings in Eli Lilly and Company were worth $5,896,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. ProShare Advisors LLC grew its stake in Eli Lilly and Company by 13.0% in the 2nd quarter. ProShare Advisors LLC now owns 145,830 shares of the company’s stock valued at $113,679,000 after buying an additional 16,805 shares during the last quarter. Profund Advisors LLC lifted its position in Eli Lilly and Company by 8.7% during the second quarter. Profund Advisors LLC now owns 12,758 shares of the company’s stock worth $9,945,000 after acquiring an additional 1,024 shares during the last quarter. King Luther Capital Management Corp boosted its holdings in shares of Eli Lilly and Company by 11.3% during the second quarter. King Luther Capital Management Corp now owns 166,483 shares of the company’s stock worth $129,778,000 after acquiring an additional 16,841 shares during the period. PFG Advisors grew its position in shares of Eli Lilly and Company by 558.2% in the second quarter. PFG Advisors now owns 26,988 shares of the company’s stock valued at $21,038,000 after purchasing an additional 22,888 shares during the last quarter. Finally, SFE Investment Counsel increased its stake in shares of Eli Lilly and Company by 13.2% during the second quarter. SFE Investment Counsel now owns 4,849 shares of the company’s stock worth $3,780,000 after purchasing an additional 566 shares during the period. 82.53% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on LLY. The Goldman Sachs Group boosted their price target on Eli Lilly and Company from $876.00 to $879.00 and gave the company a “buy” rating in a research note on Friday, October 10th. Cantor Fitzgerald boosted their target price on shares of Eli Lilly and Company from $925.00 to $985.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. HSBC upped their price target on shares of Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Finally, UBS Group increased their target price on shares of Eli Lilly and Company from $895.00 to $1,080.00 and gave the stock a “buy” rating in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $960.88.

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Daniel Skovronsky bought 1,000 shares of the firm’s stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the transaction, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. The trade was a 0.73% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Gabrielle Sulzberger bought 117 shares of the company’s stock in a transaction dated Tuesday, August 12th. The stock was bought at an average cost of $641.18 per share, with a total value of $75,018.06. Following the acquisition, the director directly owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders acquired 4,314 shares of company stock valued at $2,766,929. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $923.35 on Monday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The firm has a market capitalization of $872.92 billion, a price-to-earnings ratio of 60.35, a P/E/G ratio of 1.21 and a beta of 0.43. The firm’s 50 day simple moving average is $799.97 and its 200 day simple moving average is $775.01. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $955.46.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same period in the previous year, the business earned $1.18 earnings per share. The company’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.